RecruitingPhase 1NCT07382908

Bioequivalence Study of BGM0504 Injection

A Single-Center, Single-Dose, Randomized, Open-Label, Single-Period, Parallel Bioequivalence Study of BGM0504 Injection in Overweight/Obese Participants

Sponsor

BrightGene Bio-Medical Technology Co., Ltd.

Enrollment

144 participants

Start Date

Dec 23, 2025

Study Type

INTERVENTIONAL

Conditions

Overweight/Obesity

Summary

This is a study to evaluate the bioequivalence of a single subcutaneous injection of BGM0504 multi-dose pen (experimental formula T1) and BGM0504 single-dose pen (experimental formula T2) with BGM0504 single-dose pen (reference formula R).

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BGM0504 Injection multi-dose pen, a drug called BGM0504 Injection single-dose pen, and others for people with overweight/obesity. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.